Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejphar.2020.173694 http://scihub22266oqcxt.onion/10.1016/j.ejphar.2020.173694 33130275!7604012!33130275     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33130275&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+J+Pharmacol 2021 ; 891 (?): 173694 Nephropedia Template TP {{tp|p=33130275|t=2021. COVID-19 and antimalarials Have we been doing it wrong all along?|pdf=|usr=}}{{33130275}} gab.com Text COVID-19 and antimalarials Have we been doing it wrong all along JO: Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33130275 #FOAvip In the context of the current SARS-CoV-2 pandemic, associations of drugs which interfere with specific steps of the viral infectious cycle are currently being exploited as therapeutic strategies since a specific treatment by vaccination is still unavailable. A widespread association of repurposed agents is the combination of the antimalarial drug Hydroxychloroquine and the macrolide antibiotic Azithromycin in the setting of clinical trials. But a closer analysis of their mechanism of action suggests that their concomitant administration may be impractical, and this is supported by experimental data with other agents of the same classes. However a sequential administration of the lysosomotropic antimalarial with the addition of the macrolide proton pump inhibitor after the first has reached a certain threshold could better exploit their antiviral potential. Twit Text FOAVip COVID-19 and antimalarials Have we been doing it wrong all along ????Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33130275 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33130275 #FOAvip English Wikipedia <ref>{{Cite pmid|33130275}}</ref> COVID-19 and antimalarials Have we been doing it wrong all along? #MMPMID33130275 Cismaru CA; Cismaru GL; Seyed Nabavi F; Seyed Nabavi M; Berindan-Neagoe I Eur J Pharmacol 2021[Jan]; 891 (?): 173694 PMID33130275show ga In the context of the current SARS-CoV-2 pandemic, associations of drugs which interfere with specific steps of the viral infectious cycle are currently being exploited as therapeutic strategies since a specific treatment by vaccination is still unavailable. A widespread association of repurposed agents is the combination of the antimalarial drug Hydroxychloroquine and the macrolide antibiotic Azithromycin in the setting of clinical trials. But a closer analysis of their mechanism of action suggests that their concomitant administration may be impractical, and this is supported by experimental data with other agents of the same classes. However a sequential administration of the lysosomotropic antimalarial with the addition of the macrolide proton pump inhibitor after the first has reached a certain threshold could better exploit their antiviral potential. |*COVID-19 Drug Treatment[MESH] |*COVID-19/virology[MESH] |*Drug Repositioning/methods/trends[MESH] |*SARS-CoV-2/drug effects/physiology[MESH] |Anti-Bacterial Agents/pharmacology[MESH] |Antimalarials/pharmacology[MESH] |Azithromycin/*pharmacology[MESH] |Drug Interactions/physiology[MESH] |Humans[MESH]COVID-19 and antimalarials Have we been doing it wrong all along?(epmc).pdf DeepDyve Pubget Overpricing